Altre lingue Easywell Biomedicals, Inc.

Azioni

1799

TW0001799005

Prodotti farmaceutici

Prezzo di chiusura Taipei Exchange Altri mercati azionari 17/04/2025			Variaz. 5gg	Var. 1 gen.
58,60 ^TWD	-0,68%		+4,09%	-8,86%

19/03	Easywell Biomedicals, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2024	CI
2024	Easywell Biomedicals, Inc. e la consociata Tulex Pharmaceuticals Inc. firmano un accordo di co-sviluppo per il TLX-050 e aggiungono un collaboratore terzo	CI

Altre lingue

Easywell Biomedicals, Inc. announced that it expects to receive TWD 99.212 million in funding from Standard Chemical & Pharmaceutical Co. Ltd.	25/03
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	19/03
Easywell Biomedicals, Inc. announced a financing transaction	12/03
Easywell Biomedicals, Inc. and Subsidiary Tulex Pharmaceuticals Inc. Signs a Co-Development Agreement for the TLX-050, and Adding a Third-Party Collaborator	17/12
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	12/11
Easywell Biomedicals, Inc. announced that it expects to receive TWD 171.6 million in funding	17/10/24
Easywell Biomedicals, Inc.(TPEX:1799) added to S&P Global BMI Index	23/09/24
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	13/08/24
Easywell Biomedicals, Inc. signed a letter of intent to acquire 40% stake in Jiangsu Huahan Pharmaceutical Technology Co.,Ltd. from Nanjing Huaxun Intellectual Property Consulting Co., Ltd. for CNY 37.5 million.	07/08/24
Easyway Biomedical Inc. and Tulex Pharmaceuticals Inc. Sign Collaborative Development Agreement with Handa Biotech and Its Subsidiary, Handa Neuroscience, LLC to Jointly Develop TLX-050	09/07/24
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05/24
Easywell Biomedicals, Inc. announced a financing transaction	08/05/24
Easywell Biomedicals, Inc.'s Subsidiary Jiangsu Huahan Pharma-Tech Co., Ltd. Obtains Approval from the Jiangsu Medical Products Administration of China for Compliance with the Good Manufacturing Practice Inspection for Pharmaceuticals	07/04/24
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03/24
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11/23
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22
Easywell Biomedicals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22
Easywell Biomedicals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22
Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21
Easywell Biomedicals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	12/08/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Easywell Biomedicals, Inc.

Azioni

1799

TW0001799005

Prodotti farmaceutici

Altre lingue

Filtri